We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Biomarker Based Blood Test Detects Colorectal Cancer

By LabMedica International staff writers
Posted on 14 Apr 2015
Print article
Image: Photomicrograph of a colon carcinoma shows architectural abnormalities that are even more severe than those of an adenoma (Photo courtesy of the University of Washington).
Image: Photomicrograph of a colon carcinoma shows architectural abnormalities that are even more severe than those of an adenoma (Photo courtesy of the University of Washington).
A test is needed that offers greater certainty and that can detect bowel cancer at an early stage and at the same time reaches the whole population. Should this be achieved with a blood test, it might lower the reluctance seen in patients towards the stool test.

From the moment that colorectal cancer cells are present in the body, the peripheral blood monocytes respond to the substances secreted by the cancer cells, and the immune system responds to this and tries to remove the cancer cells from the body. A specific role in this process is assigned to a specific type of white blood cell, the peripheral blood monocyte.

A large group Europeans scientists led by those at the Vesalius Research Center (VIB; Leuven, Belgium) used peripheral blood monocytes in order to characterize a distinct gene expression profile and to evaluate its potential as a candidate diagnostic biomarker in patients with colorectal cancer (CRC), a still unmet clinical need. They performed a case-control study including 360 peripheral blood monocyte samples from four European oncological centers and defined a gene expression profile specific to CRC. The robustness of the genetic profile and disease specificity were assessed in an independent setting.

The investigators found 43 putative diagnostic markers, which were refined and validated in the confirmative multicentric analysis to 23 genes with outstanding diagnostic accuracy. The diagnostic accuracy was robustly maintained in prospectively collected independent samples with a sensitivity of 92.6% and a specificity of 92.3%. This monocyte signature was expressed at early disease onset, remained robust over the course of disease progression, and was specific for the monocytic fraction of mononuclear cells. The gene modulation was induced specifically by soluble factors derived from transformed colon epithelium in comparison to normal colon or other cancer histotypes.

The expression changes were plastic and reversible, as they were abrogated upon withdrawal of tumor-released factors. Consistently, the modified set of genes reverted to normal expression upon curative treatment and was specific for CRC. The authors concluded that they are the first to demonstrate monocyte plasticity in response to tumor-released soluble factors. The identified distinct signature in tumor-educated monocytes might be used as a candidate biomarker in CRC diagnosis and harbors the potential for disease follow-up and therapeutic monitoring.

Massimiliano Mazzone, PhD, a professor and senior author of the study, said, “This study demonstrates how important it is to gain a thorough understanding of the role of our immune system in cancer. In this case, this knowledge will hopefully result in a new, more sensitive test to detect colorectal cancer at an early stage, so that more patients can be cured. I hope that we can soon find an industrial partner to help us achieve the following step, which is the development of the test.” The study was published on March 25, 2015, in the journal Gut.

Related Links:

Vesalius Research Center 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.